FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3133721307> ?p ?o ?g. }

• W3133721307 endingPage "e211785" @default.
• W3133721307 startingPage "e211785" @default.
• W3133721307 abstract "<h3>Importance</h3> Although neoadjuvant endocrine therapy (NET) is an alternative to chemotherapy for strongly hormone receptor (HR)–positive and human epidermal growth factor receptor 2 (<i>ERBB2</i>)–negative breast cancer, evidence is currently lacking regarding the probable survival outcomes of NET in comparison with those of neoadjuvant chemotherapy (NACT) for this cancer. <h3>Objective</h3> To evaluate all-cause mortality among patients with strongly HR-positive and<i>ERBB2-</i>negative breast cancer treated with NET vs NACT. <h3>Design, Setting, and Participants</h3> This cohort study included patients with a diagnosis of invasive ductal carcinoma (IDC) with strong HR positivity and<i>ERBB2 </i>negativity, treated between January 1, 2009, and December 31, 2016, with follow-up from the index date (ie, date of IDC diagnosis) to December 31, 2018. The data came from the Taiwan Cancer Registry Database. Data were analyzed from January to November 2020. <h3>Exposures</h3> NET vs NACT for IDC with strong HR positivity and ERBB2 negativity. <h3>Main Outcomes and Measures</h3> The primary end point was all-cause mortality. Propensity score matching was performed, and Cox proportional hazard models were used to analyze all-cause mortality among patients undergoing different neoadjuvant treatments. <h3>Results</h3> A total of 640 patients (297 [46.4%] aged 20-49 years) undergoing NET (145 patients [22.7%]) or NACT (495 patients [77.3%]) were eligible for further analysis. In the multivariate Cox regression analyses, the adjusted hazard ratio (aHR) for all-cause mortality among the NET cohort compared with the NACT cohort was 2.67 (95% CI, 1.95-3.51;<i>P</i> < .001). The aHRs for age were 1.13 (95% CI, 1.03-2.24), 1.25 (95% CI, 1.13-2.45), and 1.37 (95% CI, 1.17-3.49) for all-cause mortality among patients aged 50 to 59, 60 to 69, and 70 years or older, respectively, compared with those aged 20 to 49 years (<i>P</i> = .002); the aHR for all-cause mortality among premenopausal women was 1.35 (95% CI, 1.13-1.56) compared with postmenopausal women (<i>P</i> < .001); and that of patients with a Charlson Comorbidity Index score of 2 or greater was 1.77 (1.37-2.26) compared with those with a score of 0 (<i>P</i> < .001). The aHRs of all-cause mortality for clinical tumor stage 2, 3, and 4 compared with 1 were 1.84 (95% CI, 1.07-3.40), 1.97 (95% CI, 1.03-3.77), and 2.49 (95% CI, 1.29-4.81), respectively (<i>P</i> = .009). The aHRs for all-cause mortality by clinical nodal (cN) stages were 1.49 (95% CI, 1.13-1.99) and 1.84 (95% CI, 1.31-2.61) for cN stage 1 and cN stages 2 or 3, respectively, compared with cN stage 0 (<i>P</i> = .005); those for differentiation were 1.77 (95% CI, 1.24-2.54) and 2.31 (95% CI, 1.61-3.34) for differentiation grade 2 and differentiation grade 3, respectively, compared with differentiation grade 1 (<i>P</i> < .001). <h3>Conclusions and Relevance</h3> The findings of this study suggest that for patients with strongly HR-positive and<i>ERBB2</i>–negative IDC, NACT may be considered the first choice for neoadjuvant treatment." @default.
• W3133721307 created "2021-03-15" @default.
• W3133721307 creator A5002887909 @default.
• W3133721307 creator A5006866089 @default.
• W3133721307 creator A5020889312 @default.
• W3133721307 creator A5029427372 @default.
• W3133721307 date "2021-03-12" @default.
• W3133721307 modified "2023-10-16" @default.
• W3133721307 title "Neoadjuvant Chemotherapy or Endocrine Therapy for Invasive Ductal Carcinoma of the Breast With High Hormone Receptor Positivity and Human Epidermal Growth Factor Receptor 2 Negativity" @default.
• W3133721307 cites W1892459592 @default.
• W3133721307 cites W1955397179 @default.
• W3133721307 cites W1971983116 @default.
• W3133721307 cites W1987814657 @default.
• W3133721307 cites W2004742583 @default.
• W3133721307 cites W2042772321 @default.
• W3133721307 cites W2062071674 @default.
• W3133721307 cites W2067515394 @default.
• W3133721307 cites W2075894019 @default.
• W3133721307 cites W2087179076 @default.
• W3133721307 cites W2087393207 @default.
• W3133721307 cites W2103810558 @default.
• W3133721307 cites W2107691154 @default.
• W3133721307 cites W2107928330 @default.
• W3133721307 cites W2109462843 @default.
• W3133721307 cites W2109887943 @default.
• W3133721307 cites W2113242459 @default.
• W3133721307 cites W2114167623 @default.
• W3133721307 cites W2114252947 @default.
• W3133721307 cites W2118804515 @default.
• W3133721307 cites W2128822091 @default.
• W3133721307 cites W2128995479 @default.
• W3133721307 cites W2132619562 @default.
• W3133721307 cites W2136561378 @default.
• W3133721307 cites W2137853125 @default.
• W3133721307 cites W2154692607 @default.
• W3133721307 cites W2157250162 @default.
• W3133721307 cites W2171958606 @default.
• W3133721307 cites W2189916683 @default.
• W3133721307 cites W2233409291 @default.
• W3133721307 cites W2340608556 @default.
• W3133721307 cites W2346232596 @default.
• W3133721307 cites W2467606258 @default.
• W3133721307 cites W2756014249 @default.
• W3133721307 cites W2777418534 @default.
• W3133721307 cites W2791333261 @default.
• W3133721307 cites W2800983198 @default.
• W3133721307 cites W2803329216 @default.
• W3133721307 cites W2803497212 @default.
• W3133721307 cites W2885806294 @default.
• W3133721307 cites W2893785262 @default.
• W3133721307 cites W2918169911 @default.
• W3133721307 cites W2994917610 @default.
• W3133721307 cites W3028918158 @default.
• W3133721307 cites W3083052498 @default.
• W3133721307 cites W4213201865 @default.
• W3133721307 cites W4238776129 @default.
• W3133721307 cites W4245188527 @default.
• W3133721307 cites W4245892229 @default.
• W3133721307 cites W4248981944 @default.
• W3133721307 cites W4250351112 @default.
• W3133721307 cites W4252126641 @default.
• W3133721307 doi "https://doi.org/10.1001/jamanetworkopen.2021.1785" @default.
• W3133721307 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7955271" @default.
• W3133721307 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33710293" @default.
• W3133721307 hasPublicationYear "2021" @default.
• W3133721307 type Work @default.
• W3133721307 sameAs 3133721307 @default.
• W3133721307 citedByCount "36" @default.
• W3133721307 countsByYear W31337213072021 @default.
• W3133721307 countsByYear W31337213072022 @default.
• W3133721307 countsByYear W31337213072023 @default.
• W3133721307 crossrefType "journal-article" @default.
• W3133721307 hasAuthorship W3133721307A5002887909 @default.
• W3133721307 hasAuthorship W3133721307A5006866089 @default.
• W3133721307 hasAuthorship W3133721307A5020889312 @default.
• W3133721307 hasAuthorship W3133721307A5029427372 @default.
• W3133721307 hasBestOaLocation W31337213071 @default.
• W3133721307 hasConcept C121608353 @default.
• W3133721307 hasConcept C126322002 @default.
• W3133721307 hasConcept C143998085 @default.
• W3133721307 hasConcept C207103383 @default.
• W3133721307 hasConcept C2776694085 @default.
• W3133721307 hasConcept C2780862961 @default.
• W3133721307 hasConcept C44249647 @default.
• W3133721307 hasConcept C50382708 @default.
• W3133721307 hasConcept C530470458 @default.
• W3133721307 hasConcept C71924100 @default.
• W3133721307 hasConcept C72563966 @default.
• W3133721307 hasConceptScore W3133721307C121608353 @default.
• W3133721307 hasConceptScore W3133721307C126322002 @default.
• W3133721307 hasConceptScore W3133721307C143998085 @default.
• W3133721307 hasConceptScore W3133721307C207103383 @default.
• W3133721307 hasConceptScore W3133721307C2776694085 @default.
• W3133721307 hasConceptScore W3133721307C2780862961 @default.
• W3133721307 hasConceptScore W3133721307C44249647 @default.
• W3133721307 hasConceptScore W3133721307C50382708 @default.
• W3133721307 hasConceptScore W3133721307C530470458 @default.
• W3133721307 hasConceptScore W3133721307C71924100 @default.

• next